

AML3D TO MORE THAN DOUBLE US MANUFACTURING CAPACITY FOLLOWING A SUCCESSFUL A\$30M CAPITAL RAISE

- The Company has received firm commitments for A\$30 million through a placement of shares at A\$0.19
- Placement strongly supported by both existing AML3D shareholders and new institutional investors
- Placement proceeds will be used to more than double the manufacturing capacity of its US Technology Centre, establish a facility in the European market, continue to develop its software and technology to maintain AML3D's competitive advantage and accelerate US, Australian and global growth opportunities

AML3D Limited (ASX:AL3) ("**AML3D**" or the "**Company**") is pleased to announce it has successfully completed a two-tranche institutional placement ("**Placement**"), raising approximately A\$30 million. The Placement will result in the issuance of approximately 157.9 million new fully paid ordinary shares ("**New Shares**"), each at an issue price of A\$0.19 ("**Placement Price**") per New Share.

The Placement received overwhelmingly strong support from existing shareholders and a number of new institutional investors, with demand to participate well in excess of funds that AML3D sought to raise.

AML3D's Managing Director, Sean Ebert, commented "*This successful equity placement marks another significant milestone for AML3D with investor demand being extremely strong. We are now in an excellent position to continue to rapidly advance our US expansion from Ohio, to take advantage of the demand from the US Department of Defense, whilst exploring the European markets by leveraging the backdrop of AUKUS.*"

Accelerating US go to market strategy to benefit from US reshoring and supply chain resilience initiatives

AML3D has been guided to expect significant growth in US demand following the award, by the US Department of Defense, of a US\$951 million¹ contract to Blue Forge Alliance ("**BFA**") to boost the US Navy's Submarine Industrial Base ("**SIB**"). BFA is a US nonprofit, neutral integrator, tasked with the strengthening and sustainment of the US Navy's SIB, including scaling additive manufacturing capacity and capability.

In addition, the Company is seeing a range of opportunities within the US Energy sector as well as in the Defense Aerospace sector specifically as part of the Manufacturing Licence

¹ 10 September 2024, [Contracts for Sept. 10, 2024](#), U.S. Department of Defense

Agreement with Boeing for the manufacture of aircraft parts.

To ensure AML3D is positioned to take full advantage of these opportunities, the Company has successfully completed a Placement to sophisticated investors raising approximately A\$30 million (before offer costs).

Scaling advanced additive manufacturing across the US Navy's Submarine Industrial Base

AML3D has already supplied 6 ARCEMY® systems, fulfilled several alloy testing and component contracts and has an open-ended Manufacturing License Agreement in place with BFA. The Company expects that a significant proportion of the recent award of US\$951 million will be directed to accelerating adoption of advanced additive manufacturing technology, including AML3D's ARCEMY® systems, within the US Navy's SIB.

To meet this demand AML3D will invest A\$12 million to more than double the manufacturing capacity of its US Technology Centre in Stowe, Ohio. The enhanced Ohio facility will build and supply AML3D's ARCEMY® advanced manufacturing systems and fulfill contract manufacturing, alloy testing and prototyping contracts under the leadership of Pete Goumas, President of US Operations.

The Company will initially install up to 4 additional ARCEMY® systems for the production of manufactured parts into the existing US facility whilst looking to lease a second facility for the assembly of ARCEMY® systems for sale to customers and to the support the rollout to the US Navy defence contracting supply chain. In addition, the Company will be hiring additional engineering and technical operators to support the assembly of systems, ongoing customer support requirements as well as the production of parts.

Investment in R&D programs

AML3D will also invest up to A\$3 million to continue developing its software and technology to maintain the Company's competitive advantage as a provider of a market leading advanced additive manufacturing solution. AML3D's R&D program is also designed to expand the range of applications for its advanced additive manufacturing technology to help support the US and global defense sectors.

AML3D's Chief Executive Officer, Sean Ebert, commented *"The decision in September by the US Department of Defense to award Blue Forge an additional US\$951 million of funds is expected to help accelerate the adoption of AML3D's ARCEMY technology. My understanding is a reasonable proportion of the new funds will be directed to scaling up and integrating additive manufacturing into the US Navy's Submarine Industrial Base. The completion of this A\$30 million capital raising provides AML3D with the funds to scale up our US operations to maximise this opportunity."*

The Placement also allows us to accelerate development of our software and technology to maintain our market leading position in additive manufacturing, to maintain our competitive advantage and drive growth and value creation for our new and existing shareholders."

President of AML3D's US President, Pete Goumas, said *"I've been leading AML3D's US operations for a little over a year now. In that time, we have established a state-of-the-art technology centre and manufacturing facility in Ohio, while continuing to win new contracts. I have recruited some of the best and brightest to build out our technical, sales and service teams. It is really exciting to see this surge in investment into additive manufacturing by the US Department of Defense, particularly into the Submarine Industrial Base where AML3D*

has been building its presence. The US team is fully primed and ready to rapidly expand our operations and people to meet this new and potentially significant demand for our technology.”

United Kingdom / European expansion

AML3D will explore the opportunities within the UK and European markets through establishing a location for one Arcemy system as a production and demonstration system for the market. The Company is experiencing similar demand signals as it experienced in its entry to the US market and currently has a bid in for a system to a defence related customer which it expects to secure. The base in Europe will be a showcase Technology Centre for Europe and will be there to initially support the demand we are experiencing from the backdrop of AUKUS.

PLACEMENT DETAILS

The capital raising will be by way of a Placement of approximately 157.9 million new fully paid ordinary shares, at A\$0.19 per share, comprising:

- a placement of 94.2 million shares to raise up to A\$17.9 million utilising the Company’s available placement capacity under ASX Listing Rule 7.1 and 7.1A (“**Tranche 1 Placement**”); and
- a placement of 63.7 million New Shares to raise up to A\$12.1 million, subject to shareholder approval, (“**Tranche 2 Placement**”), for the purpose of ASX Listing Rule 7.1.

The Placement Price of A\$0.19 per New Share represents a:

- 17.4% discount to the last closing price of A\$0.23 per share on 19 November 2024;
- 18.1% discount to the 5-day VWAP of A\$0.232 per share up to and including 19 November 2024; and
- 13.9% discount to the 10-day VWAP of A\$0.221 per share up at and including 19 November 2024.

The New Shares will rank pari passu with AML3D’s existing ordinary share capital.

The Company is aiming to hold the extraordinary general meeting of shareholders on 20 December 2024 for the approval of the Tranche 2 Placement.

Bell Potter Securities and Shaw and Partners Limited acted as Joint Lead Managers and Joint Bookrunners to the Placement.

PLACEMENT USE OF FUNDS

Proceeds from the Placement will be utilised to more than double manufacturing capacity at AML3D’s US Technology Centre (approximately A\$12 million), to take advantage of an anticipated step change in demand from the US Defense sector for AML3D’s advanced additive manufacturing technology and other global opportunities. The expansion of the US business to include a second site for the assembly and production of ARCEMY® systems will be critical in supporting the expected demand for systems from customers in the US.

The Company will invest approximately \$5 million in exploring the UK and European market with a view of establishing a single Arcemy unit for production and showcasing the technology to the market.

In addition, the funds raised from the Placement will be used to invest in R&D programs to maintain AML3D's competitive advantage as a provider of market leading advanced Wire-Arc Manufacturing Technology, (approximately A\$3 million). The balance of funds from the capital raising will be used to fund AML3D's working capital to accelerate US, Australian and global growth opportunities and offer costs.

INDICATIVE TIMETABLE:

Event	Date
Trading halt lifted and AL3 shares recommence trading on ASX	22 November 2024
Settlement of Tranche 1	27 November 2024
Allotment of New Shares under Tranche 1	28 November 2024
Extraordinary General Meeting (indicative)	20 December 2024
Settlement of Tranche 2 (indicative)	27 December 2024
Allotment of New Shares under Tranche 2 (indicative)	30 December 2024

* The dates in this table are indicative only and the Company reserves the right to vary these dates.

The above timetable is indicative only and subject to change. AML3D reserves the right to amend any of these dates at its absolute discretion, subject to the Corporations Act 2001 (Cth), the ASX Listing Rules and any other applicable laws. The quotation of the New Shares is subject to approval from the ASX. All references to date or time in the indicative timetable is a reference to Sydney time.

This announcement has been authorised for release by the Board of AML3D.

For further information, please contact:

Sean Ebert

Managing Director

AML3D Limited

T: +61 8 8258 2658

E: investor@aml3d.com

Hamish McEwin

Chief Financial Officer

AML3D Limited

T: +61 8 8258 2658

E: investor@aml3d.com

About AML3D Limited

AML3D Limited, a publicly listed technology company founded in 2014, is disrupting metal part supply chains using the Company's patented Wire Additive Manufacturing (WAM®) process. WAM® combines state-of-the-art welding science, robotics automation, materials engineering and proprietary software to lead metal additive manufacturing globally. AML3D is the OEM of the ARCEMY® industrial metal 3D printing systems. ARCEMY® uses WAM® to provide advanced, automated, on-demand, point-of-need 3D manufacturing solutions that are more efficient, cost-effective and have better ESG outcomes compared to traditional casting, forging and billet machining processes. ARCEMY® is IIoT and Industry 4.0 enabled to allow manufacturers across Aerospace, Defense, Maritime, Manufacturing, Mining and Oil & Gas to become globally competitive. AML3D also provides metal 3D printing design engineering services, software licencing, technical support, consumable sales and contract manufacturing services.